Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement

scientific article published on 29 September 2017

Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3389/FNEUR.2017.00521
P932PMC publication ID5626834
P698PubMed publication ID29033893

P2093author name stringRaghav Govindarajan
Nakul Katyal
P2860cites workRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Q24201081
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional studyQ24600803
Electrical impedance myography as a biomarker to assess ALS progressionQ24615680
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialQ24651555
From animal models to human disease: a genetic approach for personalized medicine in ALSQ26741250
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Q26823418
Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseasesQ28139487
Biomarkers and surrogate endpoints: preferred definitions and conceptual frameworkQ28203935
Phase II/III randomized trial of TCH346 in patients with ALSQ28241484
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosisQ28486263
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injuryQ28511628
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosisQ28728672
Electrodiagnosis in Persons With Amyotrophic Lateral SclerosisQ29013127
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutationQ29547561
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosisQ29619074
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialQ30432762
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.Q30440341
Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosisQ30485762
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.Q30494108
A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicityQ30626279
Empirical evidence of design-related bias in studies of diagnostic testsQ30776370
Biomarkers in amyotrophic lateral sclerosisQ33392844
Electrical impedance myography: Background, current state, and future directionsQ33666081
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Q33909851
Motor unit number estimation in human neurological diseases and animal modelsQ34263978
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsQ34327603
Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and researchQ34401653
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyQ34552316
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.Q34584573
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trialQ34648924
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosisQ35015986
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designQ35210258
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trialsQ36148492
Diagnostic investigation and multidisciplinary management in motor neuron diseaseQ36346085
ALS biomarkers for therapy development: State of the field and future directionsQ36479616
Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based studyQ80140620
Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic miceQ80786193
Test-retest reproducibility of 50 kHz linear-electrical impedance myographyQ83213101
[Analysis of reasons for the late diagnosis of amyotrophic lateral sclerosis]Q83367680
Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trialQ83978302
Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosisQ84990896
Reproducibility of MUNIX in patients with amyotrophic lateral sclerosisQ85001543
Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosisQ94947175
Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working GroupQ36892306
Protein biomarkers for amyotrophic lateral sclerosisQ37157841
Motor unit number estimation in neuromuscular disease.Q37198723
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insightsQ37206683
Guidelines for preclinical animal research in ALS/MND: A consensus meetingQ37698628
Effects of gender in amyotrophic lateral sclerosisQ37825010
Emerging drugs for amyotrophic lateral sclerosisQ37909351
CSF markers in amyotrophic lateral sclerosisQ38007362
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?Q38260277
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialQ39344567
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.Q39525418
Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stageQ40351989
A clinical trial of creatine in ALS.Q40469445
Histological Bulbar Manifestations in the ALS Rat.Q41137506
'Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disordersQ41927184
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trialQ42940220
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trialQ43239620
Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) miceQ43261428
Brain and plasma riluzole pharmacokinetics: effect of minocycline combinationQ43280641
Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trialQ44368657
The use of statistical MUNE in a multicenter clinical trialQ45022449
Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosisQ45075692
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.Q46281670
Modelling the effects of penetrance and family size on rates of sporadic and familial diseaseQ47360537
The cortical silent period and amyotrophic lateral sclerosisQ48183634
Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosisQ48355423
Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.Q48874060
C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS.Q48923374
Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutQ49157605
Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.Q50592658
Bayesian statistical MUNE method.Q51915464
Degenerative Myelopathy in a Bernese Mountain Dog with a Novel SOD1 Missense MutationQ56627315
We have a problem: why have ALS trials been negative?Q56929747
Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathyQ57129367
A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosisQ57666978
Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patientsQ58125524
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALSQ58271878
Shortening the time to the diagnosis of amyotrophic lateral sclerosis: role of the neurologistQ58281701
Preclinical research: Make mouse studies workQ59058234
Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic studyQ71654443
Transcranial magnetic stimulation as a diagnostic and prognostic test in amyotrophic lateral sclerosisQ71832728
A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosisQ73089745
Of mice and men: reconciling preclinical ALS mouse studies and human clinical trialsQ73194258
Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degenerationQ73348009
Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1Q79405492
Trial of celecoxib in amyotrophic lateral sclerosisQ79794799
P921main subjectamyotrophic lateral sclerosisQ206901
P304page(s)521
P577publication date2017-09-29
P1433published inFrontiers in NeurologyQ15817039
P1476titleShortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement
P478volume8